Merida Biosciences to be acquired by Lilly in $2.875 billion deal
Lilly is acquiring Merida Biosciences in a deal valued at up to $2.875 billion. The purchase is part of the drugmaker's expansion into autoimmune treatments.

Reported from
Start the conversation
Nobody has said anything yet. No account, no email — a name is optional.
Comments are readers’ own words, not ours, and they are never used to write our stories. What we keep



